# Re-evaluation Task: HN3-051

## Context
- **Case ID**: HN3-051
- **Cancer type**: Basaloid squamous cell carcinoma of the hypopharynx
- **Stage**: T3N2M0 (Stage IVA) — HPV p16-negative, Ki-67 60%
- **Molecular profile**: HPV p16-negative, Ki-67 60% (high proliferation index), Basaloid SCC histologic variant, Malnutrition BMI 19
- **Report file**: experiment_reports\HN3-051_report.json
- **Current score**: 72/100
- **Gap analysis (local GPU)**: The lack of data on the concurrent use of Pembrolizumab + Radiation (Stand) and the induction TPF (Docetaxel/Cisplatin/5-FU) regimen are critical gaps, as they provide essential information on the efficacy and safety of these treatment combinations in HN3-051. Addressing these gaps will improve the score by providing a more comprehensive understanding of the optimal treatment strategies for patients with head and neck cancer, ultimately informing more effective treatment protocols.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| rating_calibration                  |   0/15  |   0.0% |
| evidence_depth                      |  16/25  |  64.0% |
| clinical_relevance                  |   7/10  |  70.0% |
| source_quality                      |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `rating_calibration` (0.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN3-051_report.json`.

Your task: Fix ONLY the `rating_breakdown` fields in the `treatments` array.

For each treatment, verify:
1. `evidence_level.score` matches the actual study phase:
   - Phase 3 RCT (N>=500, top journal) = 9-10
   - Phase 3 RCT (N<500) = 7-8
   - Phase 2 = 5-7
   - Phase 1 = 2-4
   - Case series / retrospective = 1-3
2. `survival_benefit.score` matches actual OS delta:
   - >12 months delta = 9-10
   - 6-12 months = 7-8
   - 3-6 months = 5-6
   - 1-3 months = 3-4
   - <1 month or no control = 1-2
3. `composite_rating` = weighted average (evidence 30%, survival 30%, access 15%, safety 15%, biomarker 10%)
4. Treatments must be re-sorted descending by composite_rating after changes

Do NOT change any other field. Return the complete corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Basaloid squamous cell carcinoma of the hypopharynx",
    "stage": "T3N2M0 (Stage IVA) — HPV p16-negative, Ki-67 60%",
    "molecular_profile": [
      "HPV p16-negative",
      "Ki-67 60% (high proliferation index)",
      "Basaloid SCC histologic variant",
      "Malnutrition BMI 19"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Definitive Concurrent Cisplatin + Radiation (Standard CRT)",
      "category": "Standard of Care",
      "composite_rating": 0,
      "rating_breakdown": {
        "evidence_level": {
          "score": 9,
          "rationale": "Phase 3 RCTs (RTOG 0129, RTOG 0522, Intergroup 0126) established high-dose cisplatin (100 mg/m2 q3w) with concurrent RT as standard for locally advanced HNSCC. 5-year OS ~56-59% across these trials. NCCN Category 1 recommendation for T3N2 hypopharyngeal cancer."
        },
        "survival_benefit": {
          "score": 6,
          "rationale": "For hypopharyngeal SCC, median OS with definitive CRT approximately 28-36 months. 3-year DFS 41-50%. However, HPV-negative basaloid variant has worse prognosis: 35% 3-year OS for HPV-negative BSCC vs 86% for HPV-positive. Distant metastasis rate 6x higher than conventional SCC."
        },
        "accessibility": {
          "score": 9,
          "rationale": "Universally available at all cancer centers. Cisplatin and radiation therapy are standard treatments with established protocols. No biomarker requirement for eligibility."
        },
        "safety_profile": {
          "score": 4,
          "rationale": "Significant toxicity: grade 3-4 mucositis in 40-45%, dysphagia requiring feeding tube in 50-60%, nephrotoxicity, ototoxicity. Patient's malnutrition (BMI 19) substantially increases risk of treatment interruptions and toxicity. May require dose modifications or switch to weekly cisplatin."
        },
        "biomarker_match": {
          "score": 8,
          "rationale": "Standard treatment regardless of biomarker status. Applies universally to all SCC subtypes including basaloid variant. HPV-negative status does not preclude treatment but predicts worse outcomes."
        }
      },
      "mechanism_of_action": "Cisplatin crosslinks DNA strands, preventing cancer cell replication and inducing apoptosis. Concurrent radiation provides synergistic cytotoxicity through complementary DNA damage mechanisms. The combination achieves locoregional control while preserving the larynx in hypopharyngeal cancer.",
      "key_evidence": {
        "study_name": "RTOG 0129 / Intergroup Studies",
        "journal": "Journal of Clinical Oncology / NEJM",
        "year": 2010,
        "sample_size": 721,
        "os_months": {
          "treatment": 49,
          "control": 0,
          "hazard_ratio": 0.9,
          "p_value": 0.18
        },
        "pfs_months": {
          "treatment": 28.3,
          "control": 0
        },
        "orr_percent": {
    
... (truncated — read full file from experiment_reports\HN3-051_report.json)
```
